Skip to main content
Hong Liu, MD, Oncology, Williamsville, NY, KALEIDA Health

HongLiuMDPhD

Oncology • Williamsville, NY

Oncologist, Buffalo Medical Group

Join to view full profile

Dr. Liu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Liu's full profile

Already have an account?

Education & Training

  • University of Florida
    University of FloridaFellowship, Hematology and Medical Oncology, 2006 - 2009
  • University of Florida
    University of FloridaResidency, Internal Medicine, 2003 - 2006
  • University of Texas Medical Branch Hospitals
    University of Texas Medical Branch HospitalsInternship, Transitional Year, 2002 - 2003
  • UTMB
    UTMBPhD, Microbiology/immunology, 1996 - 2001
  • Beijing Medical University
    Beijing Medical UniversityClass of 1996, MD

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2008 - 2026
  • FL State Medical License
    FL State Medical License 2005 - 2010
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Press Mentions

  • Anticancer Bioscience Appoints Leader in Oncology Drug Development, Dr. Hong Liu, as US-Based VP of Clinical Development
    Anticancer Bioscience Appoints Leader in Oncology Drug Development, Dr. Hong Liu, as US-Based VP of Clinical DevelopmentJuly 14th, 2021
  • Improving Accessibility of the Australian My Health Records While Preserving Privacy and Security of the System
    Improving Accessibility of the Australian My Health Records While Preserving Privacy and Security of the SystemOctober 8th, 2020
  • Small-Molecule MMP2/MMP9 Inhibitor SB-3CT Modulates Tumor Immune Surveillance by Regulating PD-L1
    Small-Molecule MMP2/MMP9 Inhibitor SB-3CT Modulates Tumor Immune Surveillance by Regulating PD-L1September 28th, 2020
  • Join now to see all

Professional Memberships

Other Languages

  • Chinese (Mandarin)

Hospital Affiliations

Dr. Hong Liu, Dr. Hong Liu, MD, Dr. H Liu